Related references
Note: Only part of the references are listed.The role of bosutinib in the treatment of chronic myeloid leukemia
Carlo Gambacorti-Passerini et al.
FUTURE ONCOLOGY (2020)
The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data
Luigia Luciano et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Valentin Garcia-Gutierrez et al.
FRONTIERS IN ONCOLOGY (2019)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Fiona H. Tan et al.
ONCOTARGETS AND THERAPY (2019)
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study
Mael Heiblig et al.
EXPERIMENTAL HEMATOLOGY (2018)
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics
Emilie Patras de Campaigno et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases
Mickael Arnaud et al.
DRUG SAFETY (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Lauren Caldemeyer et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
Performance of the Standardised MedDRAA® Queries for Case Retrieval in the French Spontaneous Reporting Database
Helene Geniaux et al.
DRUG SAFETY (2014)
Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation
Angelina Daisy Goodrich
EXPERT REVIEW OF HEMATOLOGY (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Toshiyuki Sakaeda et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
Effect of Competition Bias in Safety Signal Generation Analysis of a Research Database of Spontaneous Reports in France
Antoine Pariente et al.
DRUG SAFETY (2012)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
F. J. Giles et al.
LEUKEMIA (2009)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Under-reporting of adverse drug reactions - A systematic review
Lorna Hazell et al.
DRUG SAFETY (2006)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)
EG Brown
DRUG SAFETY (2003)
Rates of spontaneous reporting of adverse drug reactions in France
B Bégaud et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Share Paper
